Top 100 Contractors in NAICS 325412: Pharmaceutical Preparation Manufacturing, FY2021

Parent companies by net contract obligations Oct 1, 2020 – Sep 30, 2021 Code page on GovTribe

The top 10 won 92% of FY2021 NAICS 325412 contract dollars

Ranking facts

Contract obligations
$20,610,456,989 Net of deobligations, by contracts coded NAICS 325412
Contractors
366 Parent companies with an obligation
Largest contractor
Mckesson Corporation $8.73 billion, 40.8% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $8,733,727,726
Rank history: #2 in FY2022, #1 in FY2023, #1 in FY2024 and #1 in FY2025; unchanged since FY2020.
2 $6,920,591,679
Rank history: #4 in FY2022 and not on the FY2023–FY2025 lists; unchanged since FY2020.
3 $1,913,730,016
Rank history: #3 in FY2022 and not on the FY2023–FY2025 lists; up 298 since FY2020.
4
Merck & Co. Inc. 2 awardees, including Merck Sharp & Dohme LLC
$1,208,238,023
Rank history: #6 in FY2022 and not on the FY2023–FY2025 lists; up 137 since FY2020.
5 $286,128,550
Rank history: #5 in FY2022, #43 in FY2023, #31 in FY2024 and #23 in FY2025; unchanged since FY2020.
6 $282,443,725
Rank history: #10 in FY2022 and not on the FY2023–FY2025 lists; up 87 since FY2020.
7
Astrazeneca PLC 2 awardees, including Astrazeneca Pharmaceuticals LP
$214,573,077
Rank history: #8 in FY2022 and not on the FY2023–FY2025 lists; down 4 since FY2020.
8 $95,497,600
Rank history: #11 in FY2022, #5 in FY2023, #3 in FY2024 and #3 in FY2025; down 1 since FY2020.
9 $78,144,000
Rank history: #7 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
10 $70,533,657
Rank history: #15 in FY2022, #4 in FY2023 and not on the FY2024–FY2025 lists; unchanged since FY2020.
11 $69,300,000
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
12 $63,612,248
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
13 $56,423,400
Rank history: #9 in FY2022, #20 in FY2023 and not on the FY2024–FY2025 lists; new, not ranked in FY2020.
14 $52,164,774
Rank history: not on the FY2022 list, #83 in FY2023, #99 in FY2024 and not on the FY2025 list; down 2 since FY2020.
15 $50,027,140
Rank history: #22 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
16 $49,650,000
Rank history: #14 in FY2022, #7 in FY2023, #7 in FY2024 and #6 in FY2025; down 5 since FY2020.
17 $40,121,477
Rank history: #59 in FY2022 and not on the FY2023–FY2025 lists; down 9 since FY2020.
18
Teva Pharmaceutical Industries Ltd. 2 awardees, including Teva Pharmaceuticals Usa, Inc.
$39,889,900
Rank history: #20 in FY2022, #9 in FY2023, #28 in FY2024 and not on the FY2025 list; down 2 since FY2020.
19 $27,383,575
Rank history: #19 in FY2022, #51 in FY2023, #85 in FY2024 and not on the FY2025 list; up 1 since FY2020.
20 $22,980,675
Rank history: #23 in FY2022, #17 in FY2023, #19 in FY2024 and not on the FY2025 list; down 3 since FY2020.
21 $22,501,800
Rank history: not on the FY2022–FY2024 lists and #16 in FY2025; up 7 since FY2020.
22 $21,000,000
Rank history: not on the FY2022–FY2025 lists; up 116 since FY2020.
23 $20,685,275
Rank history: #24 in FY2022, #11 in FY2023, #16 in FY2024 and #15 in FY2025; up 3 since FY2020.
24 $19,573,316
Rank history: #35 in FY2022, #26 in FY2023, #26 in FY2024 and not on the FY2025 list; up 29 since FY2020.
25 $15,295,475
Rank history: not on the FY2022–FY2025 lists; up 103 since FY2020.
26 $14,490,393
Rank history: #31 in FY2022, #16 in FY2023 and not on the FY2024–FY2025 lists; down 13 since FY2020.
27 $13,227,522
Rank history: #82 in FY2022 and not on the FY2023–FY2025 lists; down 3 since FY2020.
28 $12,528,000
Rank history: #18 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
29 $12,015,372
Rank history: #40 in FY2022, #38 in FY2023, #64 in FY2024 and #55 in FY2025; up 7 since FY2020.
30
Mylan Pharmaceuticals Inc. 2 awardees, including Mylan Specialty LP
$8,250,000
Rank history: not on the FY2022–FY2025 lists; up 165 since FY2020.
31 $7,860,287
Rank history: #38 in FY2022, #18 in FY2023, #30 in FY2024 and #37 in FY2025; down 12 since FY2020.
32 $7,541,658
Rank history: #26 in FY2022, #74 in FY2023, not on the FY2024 list and #42 in FY2025; up 38 since FY2020.
33 $7,429,407
Rank history: #36 in FY2022, #15 in FY2023, #17 in FY2024 and not on the FY2025 list; up 17 since FY2020.
34 $6,932,000
Rank history: #34 in FY2022, not on the FY2023 list, #20 in FY2024 and #65 in FY2025; down 5 since FY2020.
35 $5,501,584
Rank history: #62 in FY2022, #45 in FY2023, #83 in FY2024 and #52 in FY2025; down 5 since FY2020.
36 $5,392,015
Rank history: not on the FY2022 list, #21 in FY2023, #29 in FY2024 and not on the FY2025 list; down 21 since FY2020.
37 $5,342,798
Rank history: #49 in FY2022, #30 in FY2023, #55 in FY2024 and #83 in FY2025; down 5 since FY2020.
38 $5,330,074
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
39 $5,143,795
Rank history: #41 in FY2022, #23 in FY2023, #35 in FY2024 and #30 in FY2025; up 79 since FY2020.
40 $4,885,833
Rank history: #47 in FY2022, #63 in FY2023, #47 in FY2024 and not on the FY2025 list; up 21 since FY2020.
41 $4,554,668
Rank history: #61 in FY2022, #25 in FY2023, #36 in FY2024 and not on the FY2025 list; up 4 since FY2020.
42 $4,500,000
Rank history: not on the FY2022–FY2025 lists; up 315 since FY2020.
43 $4,399,456
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
44 $4,231,135
Rank history: #1 in FY2022, #2 in FY2023, not on the FY2024 list and #48 in FY2025; down 30 since FY2020.
45 $3,401,137
Rank history: not on the FY2022 list, #48 in FY2023 and not on the FY2024–FY2025 lists; up 21 since FY2020.
46
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG Through Heyltex Corporation
$3,375,270
Rank history: not on the FY2022–FY2025 lists; unchanged since FY2020.
47 $3,160,680
Rank history: #32 in FY2022 and not on the FY2023–FY2025 lists; down 41 since FY2020.
48 $3,089,890
Rank history: #50 in FY2022, #70 in FY2023, #37 in FY2024 and #38 in FY2025; up 10 since FY2020.
49 $2,932,777
Rank history: #63 in FY2022, #35 in FY2023, #46 in FY2024 and not on the FY2025 list; up 197 since FY2020.
50 $2,821,379
Rank history: #55 in FY2022, #27 in FY2023, #32 in FY2024 and #32 in FY2025; up 27 since FY2020.
51 $2,484,675
Rank history: #46 in FY2022, #46 in FY2023, #79 in FY2024 and not on the FY2025 list; up 39 since FY2020.
52 $2,358,381
Rank history: #71 in FY2022, #57 in FY2023, #70 in FY2024 and #35 in FY2025; down 3 since FY2020.
53 $2,266,735
Rank history: #74 in FY2022, not on the FY2023 list, #63 in FY2024 and #82 in FY2025; up 9 since FY2020.
54 $2,202,292
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
55
Greer Laboratories Inc.
$1,904,073
Rank history: not on the FY2022–FY2025 lists; up 9 since FY2020.
56 $1,900,000
Rank history: #43 in FY2022, #37 in FY2023, #53 in FY2024 and not on the FY2025 list; up 79 since FY2020.
57
Avista Pharma Solutions Inc.
$1,837,747
Rank history: #78 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
58 $1,744,211
Rank history: #42 in FY2022, #34 in FY2023, #67 in FY2024 and not on the FY2025 list; up 10 since FY2020.
59 $1,653,432
Rank history: #52 in FY2022, #40 in FY2023, #54 in FY2024 and #44 in FY2025; new, not ranked in FY2020.
60 $1,632,394
Rank history: #66 in FY2022, #55 in FY2023, #61 in FY2024 and #54 in FY2025; up 24 since FY2020.
61 $1,555,847
Rank history: #64 in FY2022, #42 in FY2023, #52 in FY2024 and #61 in FY2025; up 155 since FY2020.
62 $1,534,037
Rank history: #53 in FY2022, #36 in FY2023, #42 in FY2024 and not on the FY2025 list; new, not ranked in FY2020.
63 $1,440,626
Rank history: not on the FY2022–FY2025 lists; up 331 since FY2020.
64 $1,389,715
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
65 $1,372,634
Rank history: #48 in FY2022, #32 in FY2023, #33 in FY2024 and #33 in FY2025; up 47 since FY2020.
66 $1,362,530
Rank history: #80 in FY2022 and not on the FY2023–FY2025 lists; down 28 since FY2020.
67
Cambridge Isotope Laboratories Inc. Through Otsuka America Pharmaceutical Inc.
$1,280,312
Rank history: #58 in FY2022, #67 in FY2023 and not on the FY2024–FY2025 lists; up 64 since FY2020.
68 $1,264,767
Rank history: #77 in FY2022 and not on the FY2023–FY2025 lists; up 10 since FY2020.
69 $1,251,913
Rank history: #75 in FY2022, #54 in FY2023 and not on the FY2024–FY2025 lists; new, not ranked in FY2020.
70 $1,218,345
Rank history: #70 in FY2022, #49 in FY2023, #43 in FY2024 and #75 in FY2025; up 25 since FY2020.
71 $1,210,547
Rank history: #72 in FY2022, #58 in FY2023, #93 in FY2024 and not on the FY2025 list; up 12 since FY2020.
72 $1,200,000
Rank history: not on the FY2022–FY2025 lists; up 20 since FY2020.
73 $1,197,228
Rank history: #85 in FY2022 and not on the FY2023–FY2025 lists; down 30 since FY2020.
74 $1,186,538
Rank history: not on the FY2022 list, #76 in FY2023 and not on the FY2024–FY2025 lists; up 25 since FY2020.
75 $1,175,766
Rank history: #33 in FY2022, #19 in FY2023, #27 in FY2024 and not on the FY2025 list; up 97 since FY2020.
76 $1,164,685
Rank history: not on the FY2022–FY2025 lists; up 60 since FY2020.
77 $1,161,098
Rank history: not on the FY2022–FY2025 lists; up 25 since FY2020.
78 $1,138,200
Rank history: not on the FY2022–FY2025 lists; down 18 since FY2020.
79 $1,135,766
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
80 $1,108,448
Rank history: #69 in FY2022, #47 in FY2023, #50 in FY2024 and #97 in FY2025; up 2 since FY2020.
81 $1,044,173
Rank history: not on the FY2022–FY2025 lists; down 22 since FY2020.
82
Baxalta US Inc. 2 awardees
$1,038,551
Rank history: not on the FY2022–FY2025 lists; up 143 since FY2020.
83 $1,001,957
Rank history: #83 in FY2022 and not on the FY2023–FY2025 lists; up 71 since FY2020.
84 $994,342
Rank history: #56 in FY2022, #39 in FY2023 and not on the FY2024–FY2025 lists; up 67 since FY2020.
85 $991,644
Rank history: not on the FY2022–FY2025 lists; up 171 since FY2020.
86
Heritage Pharmaceuticals Inc.
$990,000
Rank history: #68 in FY2022 and not on the FY2023–FY2025 lists; down 11 since FY2020.
87 $989,062
Rank history: #51 in FY2022, #88 in FY2023 and not on the FY2024–FY2025 lists; new, not ranked in FY2020.
88 $985,701
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
89 $919,036
Rank history: not on the FY2022–FY2025 lists; up 82 since FY2020.
90
Grifols Diagnostic Solutions Inc. 3 awardees, including Grifols Therapeutics LLC and Grifols USA LLC
$817,005
Rank history: not on the FY2022 list, #71 in FY2023, #86 in FY2024 and not on the FY2025 list; up 26 since FY2020.
91 $814,033
Rank history: #54 in FY2022 and not on the FY2023–FY2025 lists; down 50 since FY2020.
92 $796,705
Rank history: not on the FY2022–FY2023 lists, #100 in FY2024 and not on the FY2025 list; up 86 since FY2020.
93 $744,255
Rank history: #90 in FY2022, #84 in FY2023 and not on the FY2024–FY2025 lists; up 98 since FY2020.
94 $728,584
Rank history: not on the FY2022–FY2025 lists; up 173 since FY2020.
95 $727,151
Rank history: #25 in FY2022, #10 in FY2023, #40 in FY2024 and not on the FY2025 list; down 68 since FY2020.
96
Jubilant Life Sciences Limited 2 awardees, including Triad Isotopes, Inc. and Jubilant Draximage Inc.
$722,253
Rank history: #57 in FY2022, not on the FY2023 list, #84 in FY2024 and #95 in FY2025; new, not ranked in FY2020.
97
Horizon Therapeutics USA Inc.
$688,179
Rank history: #60 in FY2022, #44 in FY2023, #97 in FY2024 and not on the FY2025 list; up 11 since FY2020.
98 $683,828
Rank history: not on the FY2022–FY2025 lists; down 63 since FY2020.
99 $680,550
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
100 $675,450
Rank history: not on the FY2022–FY2023 lists, #21 in FY2024 and not on the FY2025 list; down 67 since FY2020.
Show 75 more

100 of 366 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $21.4 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2021 ran Oct 1, 2020 – Sep 30, 2021. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2020. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2020 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 NAICS 325412 contractors in FY2021?

1. Mckesson Corporation ($8.73B), 2. Modernatx Inc. ($6.92B), 3. ELI Lilly and Company ($1.91B), 4. Merck & Co. Inc. ($1.21B), 5. Glaxosmithkline LLC ($286M), 6. Abbott Laboratories ($282M), 7. Astrazeneca PLC ($215M), 8. Bavarian Nordic A / S ($95.5M), 9. Quidel Corp ($78.1M), 10. Emergent Biosolutions Inc. ($70.5M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work